Caren van Roekel

141 Mode of progression after radioembolization in colorectal cancer patients TABLE 1. Baseline and treatment characteristics Characteristic N (%) or median with range 90 Y-resin 90 Y-glass 166 Ho No extrahepatic disease Extrahepatic disease at baseline Total N 46 (51) 20 (22) 24 (27) 48 (53) 42 (47) 90 (100) Age (years) 65 (35-84) 67 (45-78) 66 (40-84) 66 (34-84) 66 (40-84) 66 (35-84) Gender Male 33 (72) 15 (75) 17 (63) 34 (71) 31 (74) 65 (72) Female 13 (28) 5 (25) 7 (37) 14 (29) 11 (26) 25 (28) WHO performance status 0 24 (52) 15 (75) 19 (79) 29 (60) 29 (69) 58 (64) 1 19 (41) 5 (25) 5 (21) 18 (38) 11 (26) 29 (32) 2 3 (7) 0 (0) 0 (0) 1 (2) 2 (5) 3 (4) Previous chemotherapy lines 0 1 (2) 0 (0) 0 (0) 1 (2) 0 (0) 1 (1) 1 13 (28) 9 (45) 11 (46) 18 (38) 15 (36) 33 (37) 2 21 (46) 8 (40) 11 (46) 21 (44) 9 (21) 40 (44) 3 11 (24) 3 (15) 2 (8) 8 (17) 8 (19) 16 (18) Bevacizumab 29 (63) 13 (65) 13 (54) 32 (67) 23 (55) 55 (61) Capecitabine 42 (91) 18 (90) 20 (83) 41 (85) 39 (93) 80 (89) Cetuximab 2 (4) 0 (0) 1 (4) 1 (2) 2 (5) 3 (4) Cisplatin 1 (2) 0 (0) 0 (0) 1 (2) 0 (0) 1 (1) Erlotinib 0 (0) 0 (0) 1 (4) 0 (0) 1 (2) 1 (1) 5